S
Senti Biosciences Holdings, Inc.
SNTICIK 0001854270NasdaqEmerging GrowthBiological Products, (No Diagnostic Substances)DelawareFY ends Dec 31
Period
FY 2025
Revenue
$22.0K
Net Income
$-61.44M
Total Assets
—
Equity
—
Shares Out
31.14M
Op. Cash Flow
$-43.44M
Business
Senti Biosciences, Inc. is a clinical-stage biotechnology company that develops next-generation cell and gene therapies engineered with proprietary gene circuit platform technologies. Its main products and services include off-the-shelf CAR‑NK cell therapy candidates (notably SENTI-202 for hematologic malignancies and SENTI-301A/SN301A for solid tumors), gene circuits such as Logic Gating, Multi‑Arming and calibrated-release IL-15, and partnered discovery programs. Key business areas comprise an internal oncology pipeline, partnered programs with Celest, Spark and BlueRock, and outsourced manufacturing relationships. The company advances programs through clinical trials and strategic collaborations across the United States, Australia and mainland China, retaining commercialization rights outside specified China territories.
Summary from filing dated 2025-03-20
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Collaboration revenue - related party | 22,000 | 0 | 2 | 3 | 2 | |
| Research and development (including related party costs of $12,909 and $14,266 for the year ended December 31, 2025 and 2024, respectively) | 38 | 34 | 32 | 28 | 22 | |
| General and administrative | 26 | 26 | 37 | 38 | 21 | |
| Impairment of long-lived assets | 5 | 300,000 | 26 | 0 | −22,000 | |
| Total operating expenses | 69 | 61 | 95 | 66 | 43 | |
| Loss from operations | −69 | −61 | −93 | −62 | −40 | |
| Interest income | 927,000 | 948,000 | 3 | 2 | 11,000 | |
| Other income, net | 800,000 | 200,000 | −33,000 | −32,000 | −120,000 | |
| Change in fair value of Preferred Stock Tranche Liability - related party | 0 | 13 | 0 | — | — | |
| Change in fair value of contingent earnout liability | 0 | 20,000 | 200,000 | 10 | 0 | |
| Total other income, net | 7 | 8 | 9 | 12 | −15 | |
| Net loss | −61 | −53 | −71 | −58 | −55 | |
| Comprehensive loss | −61 | −53 | −71 | −58 | −55 | |
| Net loss per share, basic (in dollars per share) | −2.73 | −12.03 | −16.01 | −2.23 | −19 | |
| Net loss per share, diluted (in dollars per share) | −2.73 | −12.03 | −16.01 | −2.23 | −19 | |
| Weighted-average shares outstanding, basic (in shares) | 22 | 5 | 4 | 26 | 3 | |
| Weighted-average shares outstanding, diluted (in shares) | 22 | 5 | 4 | 26 | 3 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 16 | 48 | 36 | 58 | 56 | |
| Total current assets | 23 | 59 | 71 | 103 | 60 | |
| Restricted cash | 4 | 4 | 4 | 3 | 3 | |
| Property and equipment, net | 13 | 21 | 25 | 51 | 12 | |
| Operating lease right-of-use assets | 12 | 14 | 16 | 18 | 21 | |
| Other non-current assets | 19,000 | 105,000 | 215,000 | 283,000 | 176,000 | |
| TOTAL ASSETS | 51 | 98 | 119 | 181 | 97 | |
| Accounts payable | 3 | 1 | 1 | 1 | 5 | |
| Accrued expenses and other current liabilities | 5 | 6 | 6 | 13 | 5 | |
| Operating lease liabilities, current | 5 | 5 | 4 | 2 | 2 | |
| Deferred revenue, current - related party | 43,000 | 0 | 0 | 799,000 | 2 | |
| GeneFab sublease deferred income - related party | 304,000 | 660,000 | 989,000 | 0 | — | |
| Total current liabilities | 14 | 13 | 13 | 18 | 15 | |
| Operating lease liabilities, non-current | 24 | 29 | 34 | 35 | 21 | |
| Other non-current liabilities | 8 | 5 | 0 | — | — | |
| TOTAL LIABILITIES | 46 | 47 | 53 | 54 | 36 | |
| Commitments and contingencies (Note 13) | — | — | — | — | — | |
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of December 31, 2025 and 2024, respectively; zero and 21,157 shares issued and outstanding as of December 31, 2025 and 2024, respectively; aggregate liquidation preference of zero and $147,647 as of December 31, 2025 and 2024, respectively | 0 | 25 | 0 | 0 | 172 | |
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both December 31, 2025 and 2024; 30,879,355 and 4,829,035 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 3,000 | 1,000 | 1,000 | 4,000 | 0 | |
| Additional paid-in capital | 364 | 323 | 311 | 301 | 4 | |
| Accumulated deficit | −359 | −297 | −244 | −173 | −115 | |
| TOTAL STOCKHOLDERS EQUITY | 6 | 26 | 67 | 127 | −111 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | 51 | 98 | 119 | 181 | 97 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation | 6 | 2 | 10 | 16 | 2 | |
| Depreciation | 4 | 4 | 4 | 1 | 800,000 | |
| Change in fair value of Preferred Stock Tranche liability - related party | 0 | −13 | 0 | — | — | |
| Other non-cash charges | 39,000 | 115,000 | 35,000 | 8,000 | 0 | |
| Operating lease right-of-use assets | 2 | 2 | — | — | — | |
| Accounts payable | 2 | 797,000 | −290,000 | 186,000 | −617,000 | |
| Accrued expenses and other current liabilities | 559,000 | −671,000 | 716,000 | 2 | 3 | |
| Operating lease liabilities | −5 | −4 | 484,000 | 14 | −1 | |
| GeneFab sublease deferred income - related party | −356,000 | −329,000 | 689,000 | 0 | — | |
| Deferred revenue, current - related party | 43,000 | 0 | — | — | — | |
| Other non-current liabilities | 0 | 149,000 | 0 | — | — | |
| Net cash used in operating activities | −43 | −41 | −52 | −35 | −35 | |
| Purchases of property and equipment | −196,000 | −26,000 | −12 | −41 | −6 | |
| Proceeds from sale of property and equipment | 12,000 | 60,000 | 105,000 | 0 | — | |
| Net cash provided by (used in) investing activities | −184,000 | 34,000 | 30 | −82 | −6 | |
| Proceeds from CIRM Grant | 3 | 5 | 0 | 521,000 | 2 | |
| Payment of issuance costs | −2 | −229,000 | 0 | — | — | |
| Proceeds from private placement, net of fees paid to investor | 0 | 47 | 0 | — | — | |
| Net cash provided by financing activities | 12 | 54 | 779,000 | 119 | 68 | |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH | −32 | 12 | −22 | 2 | 28 | |
| Unpaid Issuance Costs | 34,000 | 2 | 0 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro